Drug Profile
Research programme: CNS and neurological disorder therapeutics - ACADIA
Alternative Names: AC-131; AC-186; ERβ programme - ACADIA; Estrogen receptor beta agonists - ACADIA; Nurr1 programme - ACADIA; Nurr1-retinoid X receptor agonists - ACADIA; Nurr1-RXR agonists - ACADIALatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ACADIA Pharmaceuticals
- Class Small molecules
- Mechanism of Action Dopamine modulators; Estrogen receptor beta agonists; Nuclear receptor subfamily 4 group A member 2 agonists; Retinoid X receptor agonists; Selective estrogen receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis; Neuropathic pain; Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA